Introduction
GVHD is the major complication after allogeneic hematopoietic progenitor cell transplantation (HPCT). The genesis of GVHD is attributable to donor T-cell recognition of recipient alloantigens, which results in the generation of cytotoxic effector cells and proinflammatory cytokine production. [1] [2] [3] [4] [5] In patients undergoing autologous HPCT, however, where there is no genetic disparity to induce an alloresponse, a syndrome that has clinical and histological features that are similar to allogeneic GVHD has been described. [6] [7] [8] [9] This syndrome can involve the skin, intestinal tract and liver, which are target organs that are typically affected in allogeneic GVHD. There have been two clinical scenarios in which autologous GVHD has been reported in transplant recipients. The first is in patients in whom there has been the intentional induction of the disease, typically by withdrawal of CYA immunosuppression, in an effort to induce an antitumor response. [10] [11] [12] The mechanism for autologous GVHD as a consequence of CYA withdrawal has been extensively studied and is thought to be attributable to self-reactive CD8 þ T cells that escape deletion in the thymus. [13] [14] [15] There is also a requirement for lymphoablative treatment, which is necessary to eliminate peripheral regulatory T cells and create a permissive environment for the development of autoimmunity. 16 The second group has been those patients in whom GVHD develops spontaneously in the absence of any previous immune suppressive therapy. The pathophysiology of autologous GVHD that occurs spontaneously is much less well understood, but is also thought to be attributable to a failure of self-tolerance. In contrast to allogeneic GVHD, where disease severity can vary from mild to quite severe, the severity of GVHD that occurs spontaneously in recipients of autologous HPC grafts has typically been mild and nearly all patients respond to corticosteroids. [6] [7] [8] [9] 17 Thus, the general consensus has been that this is a selflimited condition with minimal attendant morbidity. In this study, we report the development of autologous GVHD that, in contrast to these earlier studies, was severe, poorly responsive to corticosteroids and associated with a high fatality rate. All patients who developed severe autologous GVHD underwent transplantation for multiple myeloma, and this complication occurred with much higher frequency in patients undergoing second transplantations.
Materials and methods

Patient population
Between January 2000 and July 2007, a total of 386 autologous peripheral blood-derived HPCTs were performed at the Medical College of Wisconsin. The characteristics of these patients along with the diseases for which autologous HPCT were performed, conditioning regimens and total CD34 cell doses are shown in Table 1 . Of the transplants performed for patients with multiple myeloma, 223 were the first transplant that the patient received, whereas 27 were second transplantations. Twenty two of these 27 transplant recipients were within 1 year of their first HPCT and all were conducted on a BMT CTN trial comparing tandem autologous HPCT to an autologous HPCT, followed by a nonmyeloablative HLA-identical sibling transplant. The duration between first and second transplantations for the five patients in whom at least 1 year elapsed between transplants ranged from 2.5 to 5.5 years (median 4.5 years). All of the autologous HPCTs performed for non-Hodgkin's lymphoma, Hodgkin's disease or AML were first transplantations.
Flow cytometric analysis
Aliquots of HPC products from patients who developed autologous GVHD or a control group of multiple myeloma patients who were transplanted with the same conditioning regimen but failed to develop GVHD were thawed and examined for cell surface marker expression by multicolor flow cytometry. Cell samples were stained with surface fluorochrome-conjugated antibodies in FACS staining buffer containing PBS and 0.05% sodium azide (Sigma, St Louis, MO, USA). Conjugated MoAbs used in these studies were obtained from Invitrogen (Carlsbad, CA, USA) and BD Biosciences (San Jose, CA, USA). For intracellular staining, cell suspensions were first stained for surface markers, fixed with 1% paraformaldehyde, washed with permeabilization buffer (0.5% Triton-X 100), stained for intracellular antigens in permeabilization buffer (0.5% Triton-X 100) for 30 min, then washed with 0.5% Triton-X 100 and fixed in BD stabilizing buffer (Becton Dickenson, San Jose, CA, USA) before analysis. During all steps of staining, permeabilization and washing, human immunoglobulins (0.1 mg/ml final concentration; Gammagaurd, Baxter Healthcare, Deerfield, IL) were used to block nonspecific Fc receptor antibody binding. All samples were acquired on an LSRII (Becton Dickenson) and analyzed using FlowJo software (v8.2; Stanford University/Tree Star Inc., CA, USA). Lymphocyte subset analysis was performed on a live-lymphocyte gate, plus a CD45 þ /CD14 À Boolean inclusion gate. All data were evaluated by unpaired two-tailed t-test analysis using GraphPad Prism v4.0 (GraphPad Software, San Diego, CA, USA).
Results
Patient 1
The patient was a 49-year-old male who initially presented with a solitary plasmacytoma in ). The post transplantation course was complicated by an engraftment syndrome characterized by erythematous skin, fever and chills. These symptoms initially resolved without therapy, but a generalized erythematous rash recurred 23 days post-HPCT accompanied by diarrhea. He received a 2-week treatment course with prednisone (1 mg/kg/day). After a taper of steroids, however, the patient developed fever and eosinophilia and his rash worsened with diffuse erythema and palmar desquamation. Steroids were reinstituted 40 days post transplantation. A skin biopsy performed before reinstitution of therapy was read as eczematous dermatitis, although clinically the patient was felt to have an autologous GVHD-like syndrome. The patient's course was complicated by recurrent episodes of cellulitis and bacteremia because of areas of skin breakdown from his persistent rash. The patient remained on low-dose steroids and topical steroid ointments, but this failed to induce a complete remission. Six months after transplantation, he (Table 2) . This resulted in a transient partial response but his symptoms subsequently recurred. Daclizumab was begun 13 months post-HPCT for a total of five doses without any improvement. In August 2005, the patient was begun on treatment with Campath (alemtuzumab) at a dose of 10 mg three times a week, followed by a maintenance program where this agent was administered every week to every 3-4 weeks. This resulted in significant improvement with resolution of his erythema and palmar desquamation and marked improvement in the patient's quality of life. There was also normalization of transaminase values and a 70% reduction in the alkaline phosphatase level. ). The patient engrafted with an absolute neutrophil count 4500/mm 3 by day 14. His post transplant course was complicated by significant mucositis and diarrhea in excess of 1 l/day. The patient also developed fever and a rash consistent with an engraftment syndrome, which responded to treatment with corticosteroids. He was readmitted to the hospital 3 months later in January 2005 to undergo a second planned autologous peripheral blood HPC as part of the BMT CTN multiple myeloma trial described above for patient 1. The patient was in remission at the time of admission. Myeloid engraftment was achieved by day 14. Approximately 2-3 weeks post transplantation, the patient developed a generalized rash and large volume diarrhea in excess of 2 l/day. Pathological examination of the small intestines 26 days post transplantation revealed apoptotic enterocytes and a mixed mononuclear and lymphocytic infiltrate compatible with GVHD, as well as the presence of microsporidial organisms by electron microcospy. The patient's diarrhea did not respond to anti-protozoal therapy with albendazole and, on day 41, he developed a diffuse erythematous rash. Subsequent re-examination of the upper and lower gastrointestinal tract 2-3 weeks later, because of persistent diarrhea in excess of 2 l/day, revealed apoptotic cells and inflammatory infiltrates consistent with GVHD in the stomach, duodenum and colon. Treatment with corticosteroids (2 mg/kg/day) resulted in partial improvement, but he remained unable to tolerate food and continued to require total parenteral nutrition. Salvage therapy with etanercept, octreotide and budesonide resulted in further improvement, but the patient was still unable to tolerate enteral nutrition without recurrence of gastrointestinal symptoms (Table 2) . He ultimately developed polymicrobial pneumonia while on continuing immunosuppressive therapy and died in remission from his myeloma 160 days post transplantation.
Patient 3
The patient was a 50-year-old male who was diagnosed with ). Pre-transplantation mobilization therapy was performed with CY and G-CSF. Five days post transplantation, he developed mucositis, abdominal pain and diarrhea in excess of 1 l/day with radiographic findings demonstrating wall thickening in the descending and sigmoid colon. Fifteen days post transplantation, at the same time that myeloid engraftment was achieved, the patient had a seizure. Viral studies were negative; however, magnetic resonance imaging was deemed to be consistent with a demyelinating process. The patient was treated with a prolonged course of dexamethasone along with i.v. Ig, and his mental status ultimately returned to baseline with no further recurrence of seizures. On day 17, he developed acalculous cholecystitis and underwent a laparoscopic cholecystectomy. Because of chronic diarrhea, the patient underwent a colonoscopy 41 days post transplantation with pathological changes in the colon, demonstrating crypt abscesses and apoptotic enterocytes consistent with GVHD. The patient's diarrhea eventually resolved by day 60 while on steroid therapy for his central nervous system disorder. The patient subsequently developed an erythematous rash and eosinophilia 64 days post transplantation, which transiently improved but ultimately worsened with extensive desquamation despite increased doses of corticosteroids. On day 128 post transplantation, while on steroids, the patient developed nausea, vomiting and diarrhea. Colon biopsy was again consistent with a diagnosis of GVHD. A BM examination and immunofixation studies revealed no evidence of myeloma. The corticosteroid dose was further increased, but diarrhea persisted and he was subsequently treated with budesonide and campath without resolution of symptoms (Table 2) . A re-biopsy of the colon 150 days post transplantation showed persistent autologous GVHD of the colon. On day 172 post transplantation, the patient, who had never achieved platelet transfusion independence, died from a large intracerebral hemorrhage in the left hemisphere.
Patient 4
The patient is a 54-year-old male who was diagnosed with . The post transplant course was complicated by the development of diarrhea in excess of 4 l/day within the first week post transplantation. This was initially attributed to conditioning regimen toxicity, but due to persistent diarrhea the patient underwent a colonoscopy 13 days post transplantation, which revealed ulceration in the terminal ileum. Pathological examination of both the ileum and colon revealed extensive crypt dropout and ulcerations consistent with autologous GVHD (Figure 1 ). The patient was treated with i.v. corticosteroids and budesonide, which resulted in a significant decline in his stool volume but not a complete response. Because of persistence of symptoms, the patient was begun on therapy with campath 22 days post-HPCT. The patient had an excellent clinical response and was eventually able to be taken off total parenteral nutrition and resume a normal diet (Table 2) . He was managed on a regimen of tapering doses of steroids and campath without recurrence of symptoms. He eventually had recurrence of his myeloma 103 days post transplantation and died in hospice. ). The patient developed watery diarrhea 10 days post transplantation that was initially ascribed to a clostridium difficile infection because of a positive toxin test. Therapy with oral vancomycin, however, failed to resolve his symptoms. Colonoscopy performed 25 days after HPCT revealed multiple areas of erythema and apoptotic enterocytes diagnostic of autologous GVHD. The patient was then treated with i.v. steroids (1 mg/kg) and received a single dose of campath (10 mg) 4 weeks post transplantation. He subsequently developed an upper gastrointestinal bleed and endoscopy showed ulcerations and friable mucosa with visible bleeding vessels in the duodenum that were cauterized with an argon laser. Pathology was negative for viruses and GVHD. Steroids were discontinued due to concern that his upper gastrointestinal bleed was attributable to high-dose steroid therapy. The patient continued to have in excess of 1 l of watery stools per day and required total parenteral nutrition for adequate caloric intake. Repeat upper endoscopy 2 weeks later revealed healed ulcers but biopsies were consistent with persistent GVHD. A capsule endoscopy also demonstrated ulceration in the distal jejunum and proximal ileum all compatible with GVHD. The patient was begun on weekly infliximab (15 mg/kg) and campath (10 mg) 54 days post transplantation (Table 2) . Within 2 weeks after onset of these therapies, the patient had complete resolution of diarrhea, was able to resume normal enteral intake with discontinuation of TPN and was discharged from the hospital on day 75 post transplantation.
Cellular composition of hematopoietic progenitor cell grafts
There was no difference in the absolute number of infused CD34 þ cells per kg in patients that did or did not develop autologous GVHD (data not shown). To study the cellular composition of the grafts in more detail, aliquots from the transplanted HPC products from three patients who developed autologous GVHD and 12 patients with multiple myeloma who did not develop this complication were examined. No product was available in two of the five patients who had autologous GVHD (that is patients 1 and 2). There was no difference in the overall percentage of CD4 þ or CD8 þ T cells in the HPC products between patient groups (Figure 2a) . We also analyzed B cells from these HPC grafts as another population that has been associated with autoimmunity. In particular, memory B cells and switch memory B cells that are significantly decreased in disorders where autoimmunity is a prominent component 18, 19 were present in similar percentages as was the percentage of CD21 -B cells, a population that is expanded in these same disorders (Figure 2b ). The percentage of CD4 þ T cells that expressed the transcription factor Foxp3, which is a hallmark of regulatory T cells was also not different between products from patients with and without autologous GVHD (Figure 3 ). Co-expression of Foxp3 and CD45RO has been proposed to define the most homogenous regulatory T cell population. 20 When we analyzed this sub-population, however, we again observed no differences between these two patient groups (Figure 3) . Finally, as expression of perforin and granzyme has been correlated with the development of autologous GVHD, 21 we also examined these molecules in both CD4 þ and CD8 þ T cells. In both T-cell sub-populations, there was no observed difference in the percentage of cells that expressed perforin, granzyme A, granzyme B or a combination of these cytotoxic granules (Figure 4 ). In summary, there was no evidence that the HPC grafts from patients who subsequently developed autologous GVHD had an altered composition of T or B cells, when compared to those patients who did not develop this complication. 
À ('autoimmune-associated' B cells) in the same patient populations. The mean values are depicted by horizontal lines. There were no statistically significant differences between any of the subgroups.
Discussion
In this study, we report the development of severe lifethreatening GVHD in five patients who underwent transplantation for multiple myeloma. Although GVHD has been a not uncommon complication after autologous HPCT using either marrow or peripheral blood as the progenitor cell source, nearly all previously reported patients have responded to corticosteroids and did not develop serious clinical manifestations. [6] [7] [8] [9] 17 In fact, the most comprehensive study on autologous GVHD was recently published by Holmberg et al. 17 who reviewed 681 consecutive patients and focused on the gastrointestinal tract, where they reported an overall incidence of 13%. The upper tract symptoms such as nausea and vomiting occurred in 90% of affected patients, whereas lower tract symptoms were present in only 40% of this patient population. In the latter patients, symptoms were classified as mild, which contrasts with our patient cohort where diarrhea was often quite profuse necessitating total parenteral nutrition in four of the five patients. Notably, the mean onset of symptoms occurred early post transplantation typically within the first two weeks and often as the extension of an engraftment syndrome. Although nearly all patients in the study by Holmberg et al. (97%) responded to treatment with either one or two courses of corticosteroids, the patients reported herein only had partial responses to steroids that were characterized as failing to have a CR or flaring once steroids were tapered. There were in several instances a delay in the institution of immunosuppressive treatment from the onset of symptoms which reflected a lack of appreciation of the ultimate severity of the syndrome. However, the mean day for initiation of treatment was similar to the 45 days post transplantation reported in the study by Holmberg et al. Thus, any perceived delay in the institution in treatment in several of our patients does not appear to adequately explain the lack of response given the uniform durable responses observed in their larger population of autologous GVHD patients. Notably, the best results that we observed for treatment of this complication occurred after campath administration, which has been used sparingly, but effectively, in some patients with severe steroid-refractory acute GVHD in the allogeneic setting. [22] [23] [24] In this study, the unique observation was that all cases of severe autologous GVHD over a 7-year period occurred only in patients transplanted for multiple myeloma despite a large number of patients that were transplanted for nonHodgkin's lymphoma, AML and Hodgkin's disease. This raises the question as to whether patients with underlying multiple myeloma may be more susceptible to this complication due either to the therapy they receive or to an underlying predisposition to autoreactivity. In the former instance, one would have to postulate that exposure to specific chemotherapeutic agents would deleteriously affect either the content of regulatory cells in the HPC graft and/or endogenous cells that survive the conditioning regimen and assist in the post transplantation maintenance of self-tolerance. Nontransplant therapy for myeloma has been rapidly evolving as new therapeutic agents (for example, thalidomide, lenalidomide and bortezomib) have assumed primary roles in the treatment of these patients. [25] [26] [27] Although there was no preferential use of these drugs in this patient population relative to other patients in the myeloma cohort that does not exclude the possibility that these agents might deleteriously affect regulatory cells. In that regard, the fact that all of the observed cases of GVHD occurred since 2004, coupled with the lack of any previous reports of this complication in the many preceding years for which transplantation has been an integral component of myeloma therapy, does lead one to question the potential effects of new therapies on regulatory cell networks. This issue seems to warrant further study.
If myeloma results in an impairment in Tregs that subsequently affects the outcome in HPCT patients, one would posit that analysis of the HPC graft might be informative in this regard. For that reason, we examined the graft content from a group of myeloma patients who failed to develop autologous GVHD and compared this to three patients from whom there was remaining product available for analysis. The majority of these patients had received mobilization therapy with CY followed by G-CSF administration. We observed that the T-and B-cell phenotypes in these HPC grafts were no different in patients that did or did not develop GVHD, although admittedly the number of patients in the GVHD cohort was small. Secondly, the percentage of Tregs in these HPC products did not differ in these two patient populations. The effect of CY on T-cell subset recovery in myeloma patients has also recently been examined by Condomines et al. 28 The authors reported that CY induced a profound decrement in overall T cell numbers but had no affect on the relative proportions of naive and memory T cells within the CD4 and CD8 compartments. More relevant to our studies were their findings that the absolute numbers of Tregs had returned to pre-mobilization levels at the time of leukopheresis in contrast to total CD3 and NK cell numbers, which remained profoundly depressed. Tregs were also shown to be functional in suppression assays indicating that mobilization with CY/G-CSF does not alter Tregs either quantitatively or qualititatively. These data are consistent with our own studies indicating that mobilization therapy per se does not appear to alter Treg content in the transplanted graft.
In addition to reports of autologous GVHD, more generalized autoimmunity has also been reported in patients undergoing both single and tandem autologous transplantation for multiple myeloma, as well as other hematologic malignancies and solid tumors. Specifically, autoimmune thrombocytopenia, 29 hemolytic anemia 30 and thyroiditis 30 have been documented along with autoantibody formation. 31 Moreover, patients with underlying autoimmune disease, which is in remission at the time of transplant have had exacerbations of their disease post transplantation, 32 suggesting that the transplantation procedure may deleteriously affect the reconstituting regulatory network in some instances. What was unique in our study was that the occurrence of severe GVHD was significantly increased in those patients for whom this was their second transplantation. In fact, of patients for whom the second transplantation occurred within 1 year of first HPCT 3 of 26 or 12% developed this syndrome. In contrast, only 2 of 223 patients (0.9%) had this complication after their first transplantation (P ¼ 0.009 by Fisher's Exact test). These data suggest that the risk of developing autologous GVHD may be increased by the re-exposure to a second HPCT. The ability of Tregs to survive myeloablative doses of TBI has been reported in animal studies 33 and has been advanced as a factor that can modulate host resistance to GVHD. Thus, it is possible that re-exposure to an intensive conditioning regimen within a short period of time might cause a more significant decline in host Tregs, compared to those patients that receive only a single HPCT, and thereby open the door for immune dysregulation irrespective of a normal Treg content in the HPC product itself. Whether patients that receive tandem autologous HPCTs for malignancies other than myeloma are at increased risk for the development of autologous GVHD is not known, although, to date, this complication has not been reported to be increased in these patient populations. [34] [35] [36] [37] In conclusion, this study demonstrates that severe steroid-refractory GVHD can occur after autologous HPCT for multiple myeloma. The incidence of this complication appears to be much higher in patients receiving second HPCTs suggesting that the repetitive exposure to high-dose chemotherapy may compromise reconstitution of regulatory networks that are necessary for the maintenance of self-tolerance. This potential toxicity of tandem transplantation warrants consideration when determining the risk/benefit ratio of performing second transplantations in patients with multiple myeloma [38] [39] [40] or, perhaps, other hematologic malignancies.
